The incretin therapies glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-IV (DPP-IV) inhibitors are now well-established as second and third-line therapies and in combination with insulin for the treatment of type 2 diabetes. Over the last decade, there is accumulating evidence of their efficacy and safety from both large multicentre randomized clinical trials (RCT) and observational studies. Cardiovascular outcome trials have confirmed that several of these agents are also non-inferior to placebo with the GLP-1 RA liraglutide and semaglutide recently found to be superior in terms of major adverse cardiovascular events. Observational studies and post-marketing surveillance provide real world evidence of safety and effectiveness of these agents and have provided reassurance that signals for pancreatitis and pancreatic cancer seen in clinical trials are not of major concern in large patient populations. Well-designed real world studies complement RCTs and systematic reviews but appropriate data and methodologies, which are constantly improving, are necessary to answer appropriate clinical questions relating to the use of incretin therapies. 
| INTRODUCTION
There has been an expanding evidence base for the efficacy, safety, tolerability and cardiovascular outcomes and mortality of incretin therapies since the 1980s. They are now well-established in international diabetes treatment algorithms as second or third-line therapies and in combination with insulin. 1 Real world data are collected outside the controlled restrictions of RCTs and are therefore more representative of usual clinical practice. 3 Specific differences that can be identified include the fact that there is a clear sequence of outcomes with RCT and a wider range of outcomes with real world studies, follow-up is longer with real world studies and in general they are cheaper to conduct compared with RCTs. RCTs are often highly selective and exclude elderly patients (65 years and older), those with co-morbidities or taking other drugs whereas in real world practice, patients are often older than 65 years, suffer from multiple diseases and take several drugs and can be classified as "diverse and complex." 4 This review will consider what has been learnt from these two important but different sources of evidence for determining the place of incretin therapies in current type 2 diabetes management. 
| INCRETIN THERAPIES

| Clinical research trials
A RCT is considered the gold standard when assessing new interventions and therefore systematic reviews and meta-analyses with homogeneity of RCT are the highest level of evidence. Real-world data and observational studies provide important clinical data and outcomes beyond that gained from RCT and help us to understand the true impact of the intervention including its effectiveness, costeffectiveness and adverse effects ( Figure 1 ). Whereas RCT answer the question "can it work?" real world data are more concerned with answering "does it work?" 12 The primary focus of RCTs is efficacy, safety, quality and cost-effectiveness. Real world studies extend this to assess effectiveness, safety, quality, cost-effectiveness, natural history, compliance and adherence as well as identifying service models and patient preference (Table 1) .
| Efficacy and tolerability
The glycaemic efficacy of incretin therapies has been demonstrated by a number of systematic reviews and meta-analyses (Table 2) .
Some have been conducted using GLP-1 RA alone and others on DPP-IV inhibitors. With time, there has been greater diversity in the clinical trials included in systematic reviews and meta-analyses in terms of study duration, geographical spread, comparison of at least 2 active treatments and phase III trials.
The first systematic review and meta-analysis of incretin therapy was published in 2007. 13 RA and DPP-IV inhibitors (−1.2% vs 0.8% vs 0.7%, respectively, both P < 0.0001). 15 As expected, both short-and long-acting GLP-1 RA reduced weight whereas DPP-IV inhibitors were weight neutral. Conclusions could not be made for lipids, blood pressure and heart rate due to inconsistencies in reporting and except for gastrointestinal (GI) symptoms with GLP-1 RA, adverse effects were rarely observed.
A meta-analysis of the effect of GLP-1 RA on body weight examined 29 studies (n = 10 275) of at least 24 weeks' duration that reported body weight data at either 6 months and/or 12 months. 16 In the 19 studies in patients with diabetes, GLP-1 RA were associated with significant BMI reduction of 1.2 kg/m 2 (95% CI −1.5 to −0.8, P < 0.001) at 6 months and 1.9 kg/m 2 (95% CI −3.0 to −0.8, GLP-1 RA are associated with increased GI side-effects especially on initiation and with short-acting agents. The evidence suggests that GI side-effects although initially troublesome resolve after a few weeks. It is important to discuss expectations with patients before initiation of these therapies, in particular stressing that nausea is likely to be mild and transient, resolving within a few weeks, that it may be a symptom of fullness and that reducing portion sizes and fat content might alleviate discomfort. It may be useful for patients to keep a log of nausea-inducing foods and slow titration is also likely to help. Severe persistent abdominal pain may however be an early sign of acute pancreatitis which again is shown by systematic reviews and observational studies to be a relatively rare but important adverse effect of GLP-1 RA. In general, GLP-1 RA should be avoided in severe GI disease including gastroparesis.
| Safety
There is ongoing controversy as to whether GLP-1 RA are associated with pancreatitis and pancreatic cancer. outcomes with some concern regarding increased hospitalization with heart failure with saxagliptin and alogliptin resulting in alerts from the FDA to avoid these agents in certain patient circumstances such as pre-existing heart or renal failure. It is beneficial therefore to examine systematic reviews and meta-analyses of incretin therapies on cardiovascular outcomes and mortality to determine whether the evidence supports the findings of individual trials. However, making comparisons between and conducting statistical analyses of multiple trials is affected by heterogeneity of studies due to differences in methodology, trial duration, outcome measures and sample size (Table 2) .
Overall, cardiovascular safety is not affected by incretin therapies as confirmed by a recent systematic review of 11 pooled analyses, 17 meta-analyses and 8 RCTs of patients exposed to DPP-IV inhibitors or GLP-1 RA up to 4 years. 26 A systematic review found a nonsignificant increased risk in hospitalization for congestive heart failure with DPP-IV inhibitors (HR 1.14, 95% CI 0.97-1.34, P = 0.10) 27 but the meta-analysis was significantly affected by heterogeneity on all-cause mortality in patients with T2DM. 31 No difference in allcause mortality was detected when comparing incretin therapies with control (OR 0.96, 95% CI 0.90-1.02, I 2 = 0%); although there was the suggestion of improved mortality with GLP-1 RA this was not strongly supported by subgroup analysis.
The impact of incretin therapies on inflammatory markers such as C-reactive protein (CRP) and tumour necrosis factor-alpha (TNF-α) Data were available on 4857 patients of which 39.6% were on insulin 95% CI −0.47 to −0.18; P < 0.0001). 5 However, in this study, liraglutide was more effective at achieving weight loss (−3.24 kg vs −2.87 kg, respectively).
ABCD also conducted an audit on the safety and efficacy of liraglutide 1.2 mg daily in 1791 patients with mild and moderate renal impairment and found that at 6 months there were significant reductions in HbA1c (−1.0 to −1.1%) and weight (−3.6 to −3.8 kg) which was not affected by degree of renal function. 41 Minor hypoglycaemia
was not more commonly reported in those with renal impairment and 
The concerns around pancreatic safety of incretin therapies and the emergence of safety signals from post-marketing surveillance led to independent evaluations by the FDA and EMA of extensive data from toxicology studies in rodents and non-rodents as well as clinical safety databases. 45 The FDA evaluation examined 41 000 participants exposed to incretin drugs in over 200 trials and the EMA reviewed all studies undertaken in the European Union with these agents. The overall conclusion was that the data provided reassurance that there was no compelling evidence that GLP-1 RA and DPP-IV inhibitors were linked with an increased risk of pancreatitis and pancreatic cancer although both agencies would continue to monitor the association as a safety signal.
An international multicentre population-based cohort study con- . 47 Another review of the literature concluded that the current literature was inadequate and longer-term studies will be necessary to evaluate this association further. 48 Another systematic review sought to answer this concern by evaluating data from 6 observational studies (n = 2 229 470), 5 in the United States and 1 in Italy, comparing incretin therapies with other treatment and pancreatitis risk. 49 The review found no difference in 
| Cardiovascular outcomes and mortality
Data from observational studies of incretin-based therapies have been conflicting. An observational study examined the risk of hospitalization for heart failure with saxagliptin and sitagliptin by reviewing 18 health insurance and health system data partners in US FDA's Mini-Sentinel programme which comprised 78 553 patients on saxagliptin and 298, 124 patients on sitagliptin. 51 The study showed that, contrary to evidence from cardiovascular outcome trials (CVOT) for these agents, there was no increased risk of hospitalization for heart failure compared with other agents such as pioglitazone, sulphonylureas or insulin and regardless of pre-existing cardiovascular disease.
Another analysis used healthcare data obtained from 3 countries, to investigate the association between heart failure and incretin therapies. 52 The study found that in 1 499 650 patients with 29 741
episodes of heart failure requiring hospitalization with an incidence rate of 9.2 events per 1000 persons per year, there was no increased risk of this outcome compared with other oral glucose lowering agents for GLP-1 RA (HR 0.95, 95% CI, 0.83-1.10) or DPP-IV inhibitors (HR 0.84, 95% CI, 0.69-1.02) ( Table 3 ).
The safety of DPP-IV inhibitors with regard to heart failure hospitalization has also been confirmed in another very large observational retrospective registry study of 127 555 patients in the Nationwide OsMed Health-DB Database covering 32 health services in 16 Italian regions (HR 0.70; 95% CI 0.52-0.94; P = 0.018). 53 The findings of these massive observational studies of real world data provides some reassurance regarding this serious outcome, despite the conflicting results from RCTs for DPP-IV inhibitors.. [28] [29] [30] 54 The UK Prospective Diabetes Study Risk Engine has been used in an observational retrospective study in 170 patients with type 2 diabetes in Italy on sitagliptin to evaluate cardiovascular risk evolution and found analysis of variance testing showed a significant effect on increased CV risk at 12 months (P = 0.003) and 48 months (P = 0.04). or adverse events. 59 The authors concluded that other than the surrogate endpoint of improved glycaemic control, data on clinically relevant benefits of DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in older adults is scarce. 60 Pooled analysis of phase III trials for liraglutide 61 and dulaglutide in people with diabetes >65 years have shown that they can be used safely and effectively in this cohort. 
65
A small (n = 58) observational study comparing the effect of metformin in combination with one of liraglutide, exenatide, sitagliptin, pioglitazone and gliclazide on NAFLD found no difference between therapies on qualitative ultrasonographic evaluation after 6 months. 66 
| CONCLUSION
While RCTs continue to provide high-quality evidence of the efficacy and safety of incretin therapies, it is only through systematic reviews and meta-analyses that findings can be understood in aggregate.
However, there can be considerable variation in quality of systematic reviews, and this needs to be considered by stakeholders involved in making clinical and health economic decisions regarding incretin therapies. 67 Beyond research, real world data in the form of observational studies complement RCTs and provide information on a larger scale than is feasible in clinical trials although multiple confounding factors and variations in care can affect the results. Furthermore, pragmatic RCTs can overcome the criticisms of real world evidence.
Systematic reviews confirm that GLP-1 RA are safe and effective but as a group do not improve cardiovascular outcomes despite evidence from individual cardiovascular outcome trials. Head-to-head studies might identify the reasons for this. In conclusion, well-designed real world studies complement RCTs and systematic reviews but appropriate data and methodologies, which are constantly improving, are necessary to answer appropriate clinical questions. Clinicians need to be aware of the strengths and limitations of these two types of data before making informed decisions for the clinical care of their patients.
